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Abstract: 
BACKGROUND: Self-expandable metal stents (SEMS) are the main 
palliative modality used in inoperable oesophageal cancer. Other palliative 
modalities, including Argon plasma coagulation (APC), have also been 
used.  
 
OBJECTIVE: To assess the relative efficacy of SEMS and APC regarding the 
survival of patients with inoperable oesophageal cancer, not receiving 
chemo/radiotherapy.  
 
METHODS: Single centre, retrospective analysis of all patients (n=228) 
with inoperable oesophageal cancer between January 2000 and July 2014, 
not receiving chemo-radiotherapy, treated with SEMS (n=160) or APC 
(n=68) as primary palliation modalities. Cox-regression was performed to 
identify individual factors affecting survival and Kaplan-Meier curves were 
created for patients treated with APC and SEMS for stage III and IV 
disease. Survival intervals were compared by the log-rank test.  
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RESULTS: Type of treatment was the only statistically significant factor 
affecting survival, after disease stage stratification (hazard ratio-HR: 1.36, 
95% CI:1.13-1.65 of SEMS over APC, p: 0.002).  Median survival for 
patients treated with APC and SEMS was 257 (Interquartile range-IQR: 
414, 124) and 151 (IQR: 241, 61) days respectively in stage III disease. It 
was 135 (IQR: 238, 43) and 70 (IQR: 148, 32) days respectively in stage 
IV disease. Both differences were statistically significant (p=0.02 and 0.05 
respectively).  
CONCLUSIONS: APC is a promising palliation modality in inoperable 
oesophageal cancer, when patients are not candidates for chemo-
radiotherapy. A randomized controlled trial will be needed to confirm those 
results.  
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ABSTRACT 
BACKGROUND: Self-expandable metal stents (SEMS) are the main palliative 
modality used in inoperable oesophageal cancer. Other palliative modalities, 
including Argon plasma coagulation (APC), have also been used. 
 
OBJECTIVE: To assess the relative efficacy of SEMS and APC regarding the 
survival of patients with inoperable oesophageal cancer, not receiving 
chemo/radiotherapy. 
 
METHODS: Single centre, retrospective analysis of all patients (n=228) with 
inoperable oesophageal cancer between January 2000 and July 2014, not receiving 
chemo-radiotherapy, treated with SEMS (n=160) or APC (n=68) as primary palliation 
modalities. Cox-regression was performed to identify individual factors affecting 
survival and Kaplan-Meier curves were created for patients treated with APC and 
SEMS for stage III and IV disease. Survival intervals were compared by the log-rank 
test.  
 
RESULTS: Type of treatment was the only statistically significant factor affecting 
survival, after disease stage stratification (hazard ratio-HR: 1.36, 95% CI:1.13-1.65 of 
SEMS over APC, p: 0.002).  Median survival for patients treated with APC and 
SEMS was 257 (Interquartile range-IQR: 414, 124) and 151 (IQR: 241, 61) days 
respectively in stage III disease. It was 135 (IQR: 238, 43) and 70 (IQR: 148, 32) days 
respectively in stage IV disease. Both differences were statistically significant 
(p=0.02 and 0.05 respectively).  
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CONCLUSIONS: APC is a promising palliation modality in inoperable oesophageal 
cancer, when patients are not candidates for chemo-radiotherapy. A randomized 
controlled trial will be needed to confirm those results.  
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INTRODUCTION  
 
The crude incidence of oesophageal cancer in the European Union is 4.5 
cases/10
5
/year and the mortality is 3.5/10
5
/year
1
. Even after complete tumour 
resection the long term survival in localized disease with lymph node involvement 
does not exceed 25%. In extensive disease the combination of surgery with other 
treatment modalities is a standard approach, but complete tumour resection is not 
possible in 30-50% of pT3-T4 cases
1
. The best palliative treatment for patients with 
inoperable oesophageal cancer has not yet been established. Treatment options most 
commonly used for palliation include self expandable metal stent (SEMS) placement
2-
4
, thermal ablative techniques (laser, APC)
5, 6
, external beam radiation in combination 
with brachytherapy
7
, brachytherapy as a single treatment
8
 and chemotherapy
9
. In 
many cases combination of palliative treatments are implemented. Although SEMS 
have no direct antitumour activity, they are thought to extend the survival of 
symptomatic inoperable patients by improving nutritional intake and preventing 
starvation, dehydration, and aspiration. Other studies confirmed the effectiveness of 
APC as palliative treatment in oesophageal cancer, either alone
10-12
or in combination 
with other modalities
13
.  
 
The relative effect of SEMS compared to APC on survival in patients with 
oesophageal cancer, who are not candidates for surgery or chemoradiotherapy, is 
unknown. In clinical practice, both modalities are available and in many cases they 
are both used in the same patients. The aim of this study was to compare the 
effectiveness of 2 different palliation strategies using either APC or SEMS as primary 
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treatment, followed by the other as needed, on survival of patients with inoperable 
carcinoma of the oesophagus, not receiving other palliative treatments in the form of 
chemotherapy or radiotherapy.  
 
METHODS 
 
This was a retrospective observational clinical study of consecutive patients 
with inoperable carcinoma of the oesophagus treated with SEMS or APC, conducted 
at a single centre over a 14-year period. 
 
 Patients referred for palliative treatment of oesophageal or oesophago-gastric 
junction cancers extending to the oesophagus were recruited. All had been assessed in 
a multidisciplinary upper GI cancer team (MDT) meeting, who agreed that surgery 
treatment was inappropriate because of locally advanced disease, metastases, severe 
comorbidity or combination of the above. The decision-making process was based not 
on predefined variables, but on consideration of multiple doctors’ opinions and on an 
individual basis, taking into account age, serum albumin, magnitude of weight loss, 
comorbidities and performance status. The endoscopic palliative treatment modality 
was decided based on social circumstances and patient preferences after detailed 
discussion regarding each technique’s characteristics. Informed consent was obtained 
from all patients prior to the initiation of treatment.  
 
All patients diagnosed with inoperable oesophageal or oesophago-gastric 
junction cancer (Siewert type I) between January 2000 and July 2014 and received 
either APC or SEMS were considered eligible for inclusion in this study. Patients who 
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received chemotherapy or radiotherapy either before or after SEMS or APC were 
excluded. Patients intolerant to the initial chemotherapy treatment, not being able to 
conclude a cycle of therapy were also included, since a single dose of chemotherapy 
was not considered as significant to alter the outcome. Patients lost to follow up or 
with incomplete staging or treatment data were excluded. 
 
Computerized medical records dated between 2000 and 2014 were searched 
for patients meeting the inclusion criteria. Patient cases were identified using 4 
different sources: hospital electronic records system (since 2004), the upper GI cancer 
MDT records, the electronic endoscopy reporting system and the South-East of 
Scotland Cancer network database. The following data were retrieved from the 
medical, pathology and endoscopy records as well as the death register: gender, age, 
date of diagnosis, date of first treatment, dates of subsequent treatments, date of death, 
tumour location, histology, staging and comorbidities. For the latter, the comorbidity 
component (Charlson Comorbidity Score-CCS) of Charlson Comorbidity Index (CCI) 
was used. Charlson Comorbidity Index (CCI) has been widely used and proved to be 
a reliable tool for use in trials of cancer patients.  CCI score consistently correlated 
with disease specific survival, overall survival, or treatment-related adverse events, 
confirming its predictive validity. After controlling for age, cancer stage, and type of 
treatment, increasing comorbidity remained significantly predictive of increased all-
cause mortality
14
 and, as is the case with other comorbidity indices, has been shown to 
be more predictive of disease outcome than single comorbid conditions
15
. For the 
purposes of this study, the score was calculated taking into consideration all the 
comorbidities known prior to the diagnosis of cancer. Therefore, patients without any 
other health problems apart from oesophageal cancer were assigned a CCS of 0.  
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 STAGING PROCEDURE 
 
 Staging was based on endoscopic findings, histology and imaging studies. CT 
scan of abdomen and thorax was performed in all patients, as well as an endoscopic 
ultrasound (EUS) until 2010. Since 2010 positron emission tomography (PET) scan 
was also performed and EUS was used in cases of uncertainty. Oesophago-gastric 
junction cancers extending to the oesophagus (Siewert type I) were categorized as 
lower oesophageal. The most recent edition (6
th
 or 7th)
16, 17
 of the American Joint 
Committee on Cancer (AJCC) TNM classification for oesophageal cancer available at 
the date of diagnosis was used for each case.  
 
TECHNIQUES  
 
Endoscopic procedure: All endoscopic procedures were performed under 
conscious sedation with the use of midazolam for biopsies to confirm the diagnosis of 
cancer. When EUS was performed, staging was done with a variety of radial or linear 
echoendoscopes (Olympus Corporation, Japan). In general, oesophageal dilatation 
was avoided prior to MDT discussion and management decision.  
 
ARGON PLASMA COAGULATION 
 
The APC treatment goal was tumour debulking and oesophageal lumen 
recanalization. Argon gas flow was set at 2 L/min and power at 40- 65 W. Four 
different catheters were used; 2.3 mm axial beam catheters were used most commonly 
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through standard scope channel, whereas the 3.2mm were used through an IT scope 
for extensive tumour debulking. The side fire conical beam and the circumferential 
beam catheters were used on few occasions. Both forced and pulsed APC techniques 
were used as needed. During procedures, the gas produced was regularly aspired and 
coagulum from the tip of the probe was cleaned when necessary. The duration of each 
session was between 25 and 40 min. Initially patients were treated at 2-4 week 
intervals, until achieving lumen patency and symptom relief and then were regularly 
treated at 8-12 weeks intervals. Those intervals were subject to change according to 
tumour response and symptoms recurrence. 
 
OESOPHAGEAL STENTS 
 
For patients treated with stent placement a partially covered SEMS was used. 
SEMS were available in lengths of 10, 12, and 15 cm with a proximal diameter of 23 
mm and a distal diameter of 18 mm (Ultraflex, Boston Scientific, USA). The stent 
was introduced and deployed either by direct endoscopic monitoring or a combination 
of both endoscopic and fluoroscopic monitoring. When the latter was used, proximal 
tumour margin was identified and marked internally by injection of a radiographic 
contrast medium into the submucosa of the oesophageal wall through a sclerotherapy 
needle. After placement, deployment of the stent was assessed endoscopically and 
fluoroscopically. 
 
STATISTICAL ANALYSIS  
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The two treatment groups were compared with respect to base-line 
characteristics using Mann-Whitney U test for continuous variables and chi-square 
test for categorical variables. Analysis was based on intention to treat. Univariate 
analysis with cox-regression was performed for each of the patients’ characteristics in 
order to assess its potential association with survival. Analysis was stratified for 
disease stage. Variables found to be associated with survival in Univariate analysis 
with p≤ 0.1 were included in a multivariate cox-regression analysis. Statistical 
significance was set at 0.05 for the variables to be retained in the multivariate model.  
Differences in survival were tested with life-table analysis using the Kaplan-Meier 
method. This was constructed by using the number of days between the first 
procedure and death. Survival intervals were compared by the log-rank test. Survival 
comparisons were performed separately for stage III and IV. Survival of patients still 
alive at the time of the analysis was censored. In order to minimize the effect of 
potential selection bias (i.e. allocating more frail patients preferentially to one type of 
treatment), survival comparisons were also performed after excluding patients 
surviving less than a month. A p value of < 0.05 was considered significant. All 
analyses were performed with IBM SPSS Statistics version 21.0 (IBM Corp, Armonk, 
NY, USA).  
 
ETHICS CONSIDERATION 
  
This study was conducted in accordance with UK research ethics guidelines. After 
review by the local ethics committee, further specific ethical review and approval 
were not required, as the study was considered as a retrospective clinical audit work, 
using data already obtained as part of regular patient care. 
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RESULTS 
 
Between January 2000 and July 2014 a total of 388 patients received a 
diagnosis of inoperable oesophageal cancer and were treated with a palliative 
modality. A total of 160 patients were excluded. Of them 86 were excluded because 
they were initially treated with chemotherapy, radiotherapy or laser. Fifty patients (10 
in APC group and 40 in SEMS group) were also excluded due to inadequate staging 
data. In those patients it was unclear whether the local invasion of the tumour could 
be classified as T2 or T3 and thus it was unclear whether they should be categorized 
as stage II or III.  Further 24 patients were also excluded due to inadequate data 
regarding their treatment. The majority of those patients were referred to our centre by 
other hospitals in Scotland for stent placement and then returned to the referring sites, 
being lost from our follow-up.  Of the remaining 228 patients, 68 were treated with 
APC as a primary modality and 160 were treated with SEMS. There were 6 out of 228 
(2.6%) patients still alive at the end of follow up, 5 of who were treated with APC and 
1 with SEMS. A flow chart describing the exclusion process, as well as the need for 
further endoscopic interventions, in addition to the initial modality used, is presented 
in Figure 1.   
 
A summary of the demographic and clinical characteristics of patients finally 
included in our study is presented in Table1. Patients in APC groups were older and 
with a higher Charlson comorbidity score. Those differences were statistically 
significant. Stage distribution in the 2 groups was different, since the APC groups 
included more stage II and less stage IV patients. Stage III patients comprised 
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approximately 40% of the population in both groups. Histology type distribution was 
also different between groups with SEMS groups including squamous cancer patients 
in a higher proportion (32.5%) compared to the APC group (15.7%). Tumour location 
was not different between groups. There were no missing data for those variables, 
with the exception of tumour length, where data on 55 patients were not available.  
 
In the APC group, a median of 3 (IQR: 2, 5) APC sessions were required to 
maintain lumen patency. In 44 (64.7%) of them, APC treatment was able to maintain 
patency until death or end of follow up period (July 2014) in surviving patients. 
Twenty four of them (35.3%) required an additional endoscopic palliative treatment 
(20 stent placement, 3 balloon dilation, 1 laser). In the SEMS group, 24 (15 %) 
patients required additional treatment. Nine of them (5.6%) required APC treatment 
for tumour overgrowth, 10 (6.3%) at least a second stent, 3 required both an 
additional stent and APC, 1 received  laser treatment and 1 had eventually a 
percutaneous  endoscopic gastrostomy after a second stent placement.  
 
Results of Univariate analysis of potential factors influencing survival, along 
with the relevant hazard ratios (HR) and p values are presented in Table 2. Those 
results are stratified for disease stage.  Amongst the 7 factors examined, only 
treatment type and tumour length met the criterion (p≤0.1) for inclusion in the 
multivariate model. Results of the multivariate cox-regression are also presented in 
Table 2. Only treatment type was found to be independently associated with survival, 
with a HR of 1.36 for SEMS over APC. Tumour length also exhibited a trend, with 
longer tumours having a worse outcome, but this did not reach statistical significance 
(p=0.07).  
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The overall median survival was 257 (IQR: 485, 135) and 102 (188, 41) days 
in the APC and SEMS group respectively. Patients treated with APC had significantly 
better median survival (log rank p<0.001). Kaplan-Meier survival curves for stage III 
and IV patients treated with APC or SEMS are presented in Fig. 2 and Fig. 3 
respectively. Comparisons between treatment groups for patients belonging to less 
advanced stages were not performed due to small numbers, especially in SEMS 
group.  
 
The overall median survival of stage III patients was 158 days (IQR: 285, 84). 
Stage III patients treated with APC had a median survival of 257 days (IQR: 414, 
124), while patients treated with SEMS had a median survival of 151 days (IQR: 241, 
61). Survival of patients treated with APC was significantly better (log rank p= 0.02) 
 
Stage IV patients had an overall median survival of 83 days (IQR: 158, 32). 
Median survival of the APC group in stage IV disease was 135 days (IQR: 238, 43), 
while patients treated with SEMS had a median survival of 70 days (IQR: 148, 32). 
The difference was statistically significant (log rank p=0.05).  
 
Patients treated with SEMS had a 14-days mortality rate of 8.1%, compared to 
0% in patients treated with APC. The respective 30-days mortality rates for SEMS 
and APC were 18.8% and 5.9%. Both differences were statistically significant 
(p=0.01 for both).  
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Further analysis of the data set after excluding patients not surviving more 
than a month showed that again the type of treatment (APC or SEMS) was found as 
the only statistically significant factor in cox-regression, while stratifying for disease 
stage. In this sub-group analysis, median survival in stage III patients was 268 days 
(IQR: 425, 137) for APC, compared to 162 (IQR: 272, 99) for SEMS and in stage IV 
disease, median survival was 166 days (IQR: 243, 111) for APC compared to 97 
(IQR: 164, 59) for SEMS. The difference was statistically significant in stage III 
(p=0.04), whereas it was not in stage IV (p=0.07). The relevant Kaplan-Meyer curves 
are presented in Appendix Figures 1 and 2, while the relevant cox-regression analysis 
is presented in Appendix Table 1.   
 
DISCUSSION  
 
The aims of palliation in patients with advanced oesophageal cancer are to 
overcome dysphagia and optimize quality of life by using interventions that have 
minimal adverse events. Even though chemo-radiotherapy is an option for dysphagia 
palliation in advanced oesophageal cancer and also conveys an advantage in survival 
compared with palliative endoscopic stenting alone, 
18
 a significant proportion of 
patients are not candidates for such treatments. The palliation modalities most widely 
used in such patients is stent insertion, brachytherapy and thermal ablation 
techniques
2-8
. It has been shown, that that MDT assessment significantly improves 
staging accuracy for gastro-oesophageal cancer and ensures that correct management 
decisions are made for the highest number of individual patients. In an audit from our 
unit, overall staging accuracy as determined at the MDT meeting was high and 
resulted in only 2/118 (2%) patients being under-treated
19
. 
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SEMS are the mainstay of palliative treatment for malignant oesophageal 
obstruction. The apparent advantage of this approach is the relative ease of 
application in a single session achieving immediate results in relieving dysphagia. In 
contrast, ablative techniques require multiple sessions and significant administrative 
co-ordination efforts and therefore are less appealing, especially in busy tertiary 
centres. Nevertheless, the apparent dominance of SEMS in oesophageal cancer 
palliation over ablative techniques in not based on solid evidence. On the contrary, a 
single centre, randomized, prospective study demonstrated a significantly longer 
median survival of patients receiving Laser treatment for palliation of inoperable 
oesophageal cancer compared to patients treated with stents
5
. An increased survival of 
patients treated with various ablative techniques including APC, over SEMS, was also 
documented in a randomized, controlled, multicentre study
22
. Those results raise the 
question whether SEMS dominance on the field is at least partially explained by their 
certain advantage in logistics rather than in a clear benefit in patient palliation and 
survival. This study tried to provide some insight into this issue.  
 
Most studies regarding SEMS included patients who were unfit for 
chemotherapy and/or radiotherapy and hence median survival was low, ranging from 
68 to 145 days
2, 3, 5, 8, 18
. This is in accordance with the results of this study which 
showed an overall median survival of 102 days in patients receiving SEMS as a 
primary palliation modality.   
 
The effectiveness of APC in tumour debulking has been studied in a number 
of studies. Eickhoff et al. showed a significant effect of both pulsed and forced APC 
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in achieving tumour debulking in GI cancers, with a response to treatment exceeding 
80%.
10
 In a retrospective analysis
6
 of 83 patients who had APC for oesophageal 
malignancy, Heindorff et al. reported a mean of six APC sessions to maintain lumen 
patency. This was higher compared with the median of 3 (mean=4), reported in this 
study. This could be explained by different intervals between the consecutive sessions 
adopted by each centre.   The same study reported an average survival of 146 days in 
63 of patients who died in the investigation period, which is significantly lower 
compared with our study’s overall median survival of 257 days. However, the 
proportion of stage IV patients in the aforementioned study was 41%, which was 
significantly higher compared with our study (25.7%) in the APC group.    
 
To our knowledge, the only direct comparison of APC versus SEMS in 
inoperable oesophageal cancer so far, followed a different study design
23
. In that 
retrospective study by Kofoed et al. the study population was divided in 3 groups: 
patients receiving APC alone, SEMS alone and a combination of APC and SEMS. A 
proportion of patients in all categories also received chemo-radiotherapy. There was 
no difference in survival between “SEMS alone” and “APC alone” groups. The 
former had a mean survival of 134 days and the latter 114 days.  Significantly better 
survival was observed in patients receiving a combination of both modalities 
compared to either modality alone. Additionally, patients receiving chemo-
radiotherapy and SEMS plus/or APC had a better survival compared to the rest of the 
cohort. Direct comparison to our results is impossible since only patients with 
adenocarcinoma were included, the results were not stratified by disease stage (only 
distribution of T, N and M was reported) and patients also received chemo-
radiotherapy. Furthermore, we chose not to compare APC or SEMS alone as distinct 
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modalities, but rather compare 2 different treatment strategies: APC first, followed by 
SEMS when repeat APC was found ineffective and SEMS as primary modality, 
followed by APC in cases of tumour overgrowth. In that sense, our analysis was more 
on an intention to treat basis.  
 
This study has certain caveats. It is a retrospective, single centre study and 
results presented should be appreciated in that context. It is difficult to claim 
immunity to selection bias in a retrospective study, especially when some baseline 
characteristics are different between patient groups. Some of those patient 
characteristics would be expected to negatively affect the prognosis in the APC group 
(e.g. older age, higher Charlson comorbidity score), while the shorter median tumour 
length could potentially improve it. In order to control for all those factors and find 
the ones independently associated with survival, cox-regression was used after 
stratification for disease stage. It was clear that treatment type was the only factor 
independently correlated to survival after stratification for disease stage, in the 
multivariate analysis.  
 
In order to minimize any potential selection bias effect (i.e. assigning the most 
frail patients in the SEMS group), further analyses, excluding the patients who died in 
the first month, were performed and confirmed that the only factor found to be 
statistically significant in the multivariate model was the type of treatment (data 
shown in appendix Table 1). In addition, the survival benefit of APC remained, at 
least in stage III disease. 
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The 30-day mortality in the SEMS group was comparable to previously 
reported results ranging from 11 to 40% 
24-27
. Although such results could raise the 
concern that selection of more frail patients for SEMS could be an explanation for the 
higher mortality, it is certain from the demographic data that patient frailty was not a 
set criterion when discussing treatment options.  
 
Cost is an important factor in every medical intervention and the need for 
repeat APC applications certainly needs further consideration from this point of view. 
Virtually all patients had more than one APC application and 35.3% needed other 
endoscopic procedures (mainly SEMS placement). However, 15% of patients in the 
SEMS group also required repeat endoscopic procedures including further stent 
insertions, while re-intervention rates as high as 38%
28
 have 
been previously reported after SEMS placement. In view of the significantly higher 
cost of SEMS compared to APC catheters (approximately 5 times more expensive in 
UK), the actual difference in cost of the 2 treatment strategies  appeared to be 
determined primarily by the costs related to the number of endoscopic procedures 
rather than the cost of consumables used. Patients treated with APC survived longer 
thus had higher number of interventions resulting in higher costs. Any future 
prospective studies should address the cost effectiveness of APC versus SEMS 
placement for palliation of esophageal cancer in detail. 
 
This retrospective study has several strengths. We followed a rigorous 
protocol in patient inclusion and analysis. Staging was of very high standards, using 
all the available modalities available (CT, EUS, PET) and was based on a 
multidisciplinary decision thus making it as accurate as possible. Detailed 
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demographics were available for all patients included and procedure related factors as 
well as mortality were documented prospectively with accuracy on case notes and 
electronic records.  
 
The palliation of inoperable oesophageal cancer is a challenging issue and 
multiple factors should be taken into consideration. This study provided evidence that 
a strategy based on APC as the primary palliation modality, supplemented by the 
placement of SEMS only after APC failure or when patients become intolerable of 
repeated endoscopies, might actually provide a significant survival benefit, compared 
to SEMS as the primary treatment. Those findings need to be interpreted in the 
context of a retrospective study and therefore, further, prospective, randomized 
studies are needed to confirm those results.  
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Table 1. Baseline population characteristics in SEMS and APC treatment groups. 
Comparisons between groups were performed using the Mann-Whitney U test for 
continuous variables and chi-square test for categorical variables. Relevant p values are 
presented for each comparison. 
 Stent as first 
treatment, N=163 
APC as first 
treatment, N=70 
p value 
Age, median (IQR) 76  (70,80) 80 (72,84) 0.01 
Gender, Male N (%) 108 (66.3) 41 (58.6) 0.26 
Charlson comorbidity score, 
median (IQR) 
0 (0,2) 1 (0,2) 0.02 
Tumour length, median (IQR) 6  (4,9) 5 (3,6) <0.001 
Stage, N (%)   <0.001 
 0 0 (0) 1 (1.4) 
 I 1 (0.6) 13 (18.6) 
 II 15 (9.2) 11 (15.7) 
 III 65 (39.9) 27 (38.6) 
 IV 82 (50.3) 18 (25.7) 
Tumour location, N (%)   0.34 
 Upper 4  (2.5) 3  (4.3) 
 Mid 30 (18.4) 8  (11.4) 
 Lower 129  (79.1) 59 (84.3) 
Histology type, N (%)   0.03 
 Adenocarcinoma 106 (65) 57 (81.4) 
 Squamous 
carcinoma 
53 (32.5) 11 (15.7) 
 Other 4 (2.5) 2 (2.9) 
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Table 2. Univariate and multivariate analyses  of risk factors affecting the survival of patients 
with inoperable oesophageal cancer, not receiving chemo- or radiotherapy,  who had APC or 
SEMS as primary palliation modality, after stratification for disease stage.  The only statistically 
significant factor in both analyses was treatment type (APC or SEMS) 
 Univariable analysis Multivariable analysis 
Risk factor HR (95% CI) p value HR (95% CI) p value 
Treatment type 1.86 (1.34-2.59) <0.001 1.36 (1.13-1.65) 0.002 
Age 0.99 (0.98-1.01) 0.27   
Gender 0.98 (0.74-1.3) 0.88   
Tumour length 1.06 (0.99-1.13) 0.08 1.06 (0.99-1.13) 0.07 
Charlson comorbidity 
score 
1.04 (0.95-1.14) 0.38   
Histology  0.29   
 Adenocarcinoma (1.00)    
 Squamous 1.27 (0.94-1.72)    
 Other 1.14 (0.39-3.34)    
Tumour location  0.15   
 Lower (1.00)    
 Middle 1.15 (0.78-1.68)    
 Upper 2.07 (0.96-4.46)    
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Figure 1. Flow chart describing the screening and exclusion process of patients with inoperable oesophageal 
cancer diagnosed between 2000 and 2014, as well as the type of initial treatment they received (APC or 
SEMS). Further types of treatments required are also presented for both the APC and SEMS groups.  
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Figure 2. Kaplan-Meier survival curves for patients with stage III inoperable, oesophageal cancer, not 
receiving chemo- or radiotherapy, having either APC or SEMS as initial palliative treatment. Median survival 
was higher in the APC group (257 days, IQR: 414, 124) compared to SEMS group (151 days, IQR: 241, 61). 
This difference was statistically significant (log rank p= 0.02).  
252x157mm (300 x 300 DPI)  
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Figure 3. Kaplan-Meier survival curves for patients with stage IV inoperable, oesophageal cancer, not 
receiving chemo- or radiotherapy, having either APC or SEMS as initial palliative treatment. Median survival 
was higher in the APC group (135 days, IQR: 238, 43) compared to SEMS group (70 days, IQR: 148, 32). 
This difference was statistically significant (log rank p= 0.05).  
282x176mm (300 x 300 DPI)  
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Appendix Figure 1. Kaplan-Meier survival curves for patients with stage III inoperable, 
oesophageal cancer, not receiving chemo- or radiotherapy, having either APC or SEMS as initial 
palliative treatment. Patients surviving less than 30 days were excluded.  Median survival was 
higher in the APC group (268 days, IQR: 425, 137) compared to SEMS group (162 days, IQR: 
272, 99). This difference was statistically significant (log rank p= 0.04). 
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Appendix Figure 2. Kaplan-Meier survival curves for patients with stage IV inoperable 
oesophageal cancer, not receiving chemo- or radiotherapy, having either APC or SEMS as initial 
palliative treatment. Patients surviving less than 30 days were excluded. Median survival in the 
APC group was 166 days (IQR: 243, 111). Median survival in SEMS group was 97 days (IQR: 
164, 59). This difference was not statistically significant (log rank p= 0.07). 
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Appendix Table 1. Univariate and multivariate analyses of risk factors affecting the survival of patients 
with inoperable oesophageal cancer, not receiving  chemo- or radiotherapy, having either  APC or SEMS 
as primary palliation modality, after stratification for disease stage. Patients not surviving more than 30 
days following the first treatment session (either APC or SEMS) were excluded.  The only statistically 
significant factor in both analyses was treatment type (APC or SEMS). Tumour length was included in the 
multivariable analysis despite not being statistically significant, to enable direct comparison with the 
analysis presented in Table 2 of the main manuscript.  
 Univariable analysis Multivariable analysis 
Risk factor HR (95% CI) p value HR (95% CI) p value 
Treatment type 1.82 (1.28-2.58) 0.001 1.34 (1.09-1.64) 0.005 
Age 0.99 (0.98-1.01) 0.46   
Gender 0.97 (0.71-1.3) 0.83   
Tumour length 1.05 (0.98-1.13) 0.15 1.06 (0.98-1.14) 0.13 
Charlson comorbidity score 1.04 (0.94-1.15) 0.47   
Histology  0.34   
 Adenocarcinoma (1.00)    
 Squamous 1.28 (0.92-1.78)    
 Other 0.99 (0.29-3.41)    
Tumour location  0.63   
 Lower (1.00)    
 Middle 1.14 (0.36-3.6)    
 Upper 1.22 (0.81-1.84)    
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